This indication is approved based on improvement of NASH and liver scarring (fibrosis). There are ongoing ... the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Its lead asset, SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trials and has shown promising Phase 1a and ... (NASH), with or without fibrosis.

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic compounds for the treatment ...

Its lead asset, SFA-002, an IL-10 up-regulator in immune cells, is approaching Phase 2 clinical trial and has shown promising Phase 1a and ... (NASH), with or without fibrosis.

The Phase 1 portion -- Phase 1a portion of this study is primarily ... non-alcoholic fatty liver disease with improvement in liver fibrosis score. In parallel, we have a collaboration underway ...

The presence of T2DM not only increases susceptibility but also accelerates the progression to more severe forms such as NASH, fibrosis, and cirrhosis. High intake of saturated fats, often in red ...

The primary causes of liver fibrosis include alcohol abuse, chronic hepatitis C virus (HCV) infection, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Despite ...

The greatest Canadian basketball player ever was incredibly close to signing with Canada’s lone NBA team. But there was one unfortunate factor that weighed into Steve Nash’s decision to spurn ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...